Find and Pitch Jounalists, Get Your Story Covered

Tags: Gabapentin Oral Solution Generic Neurontin Camber Pharmaceuticals DSCSA Compliance Drug Supply Chain Security Act

	Profile	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Backlash builds against Novo’s Catalent takeover - 24 days ago BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - 3 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 4 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 4 months ago Ahead of its upcoming decision date, a competitor takes aim at KarXT - 5 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 2 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more - 9 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 10 months ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 10 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 11 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 11 months ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - 11 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 12 months ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - 12 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 12 months ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - about 1 year ago STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - about 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - about 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - about 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - about 1 year ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - about 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - about 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - about 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - about 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - about 1 year ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - about 2 months ago Up-and-comers look for an edge in the bustling ADC field - 5 months ago As BMS announces major cuts, its Karuna deal looks poised to drive growth - 7 months ago Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention - 10 months ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 3 months ago Skye Bioscience Falls Short in Glaucoma Trial, But It’s Full Steam Ahead for Obesity Program - 6 months ago Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials - 8 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 3 months ago STAT+: Ocular Therapeutix moves in the right direction, and Alnylam tries to calm some nerves - 9 months ago STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease - 10 months ago STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion - 11 months ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 3 months ago Merck cough drug doesn’t pass panel scrutiny - about 1 year ago Johnson & Johnson antiviral pill for dengue shows early efficacy - about 1 year ago
7	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 8 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 9 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 9 months ago STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug - about 1 year ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Is CAR-T safe for early-stage patients? - 8 months ago STAT+: Cytokinetics heart drug aficamten succeeds in pivotal study - 11 months ago STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer - 11 months ago Why Cerevel Therapeutics has risen 50% in three days without changing anything - 12 months ago
9	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion - 10 months ago STAT+: Travere kidney drug narrowly fails confirmatory trial following FDA approval - about 1 year ago
10	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Oncology drugmakers seek the sweet spot between efficacy and tolerability - 12 months ago Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs - about 1 year ago

Journalists covering Camber Pharmaceuticals